Download Statistical Comparison of Immunogenicity Cutpoint

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Statistical Comparison of
Immunogenicity Cutpoint Factors
Using Log Transformation
Dingzhou (Dean) Li
PharmaTx Statistics, Pfizer Global R&D
MBSW, 2010
Definitions
• Immunogenicity:
– Causing or capable of producing
an immune response.
– Unwanted for target-binding drugs
– Desired for vaccines
– Assay required for FIH
• Anti-drug antibody (ADA) :
– Binds to a portion of the drug thus preventing the drug from
binding to its target
– Affects the conformation of the drug so that when it binds to
its target it is not functional.
– Cross reactivity with endogenous proteins; greatest
regulatory concern
Immunoassays
Bridging ELISA
Bridging ECL
Sandwich (nonbridging ELISA)
SA-HRP
Biotinlabeled
drug
Detection
Antibody/reagent:HRP
ADA
ADA
ADA
Drug
Biotin
Drug
Drug Fab
From Quantitative to Qualitative
• Quantitative
– Continuous units of reference standard
• Qualitative
– Reference standard is not available
– Ordinal or nominal
• Quasi-quantitative
– Continuous units of signals
Endpoint Titer: A quasi-quantitative method
• A way of expressing [Ab] in blood or serum
• Related to the number of times you can dilute a
sample of serum and still detect Ab
• Titer = Reciprocal of the last dilution of a titration
giving a measurable effect.
– Reported log2 of the titer.
Endpoint Titer Example
2000
1000
Plate 1
RLU
800
600
500
400
300
Titer=1894222
200
cutpoint
0
1000000
2000000
Dilution
3000000
Cutpoint
• Cutpoint: Positive vs. Negative
• How to calculate cutpoint?
– Pooled negative controls (PNC)
– Cutpoint = Mean(PNC) + cα*SD(PNC)
– cα : Critical value at significance level α, depending on
underlying distribution (e.g. c0.05 = 1.645 for normal
distribution)
– Parametric or nonparametric
• Screening vs. Confirmatory
Cutpoint Factor
• For each plate in production, want to
readily get the plate-specific cutpoint
• Multiply the mean PNC by a factor
– Cutpoint = Mean(PNC) * CPF
• Need two steps…
Two Steps
• Step 1: Cutpoint factor determination
– Negative control only
• Step 2 : Production
– Negative control, positive control, patient
samples on the same plate
– Endpoint titer, inference, sensitivity, etc
Step 1: Cutpoint Factor Determination
• 150 samples distributed on 6 plates
– Sample: a serum sample from a subject
• For each plate,
– CPF (Plate) = Cutpoint (Plate)/Mean(Plate)
• Average CPF for all the plates to get an
overall CPF
– This is the CPF for Step 2
Step 1: Pooled Negative Controls
275
250
Plate5
RLU
225
cutpoint
200
175
150
125
0
10
20
30
Negative Control Sample
40
50
Determination of CPF from PNC
Cutpoint
CPF
Overall
CPF
Plate 1
Plate 2
Plate 3
Plate 4
Plate 5
Plate 6
Sub 1 Rep 1
Sub 26 Rep 1
Sub 1 Rep 2
Sub 26 Rep 2
Sub 1 Rep 3
Sub 26 Rep 3
Sub 2 Rep 1
Sub 27 Rep 1
Sub 2 Rep 2
Sub 27 Rep 2
Sub 2 Rep 3
Sub 27 Rep 3
…
…
…
…
…
…
Sub 25 Rep 1
Sub 50 Rep 1
Sub 25 Rep 2
Sub 50 Rep 2
Sub 25 Rep 3
Sub 50 Rep 3
275
1.19
150
1.25
1.15
1.21
209
1.19
1.17
1.31
Step 2: Typical Production Plate Layout
1
ID
2
3
4
5
6
7
8
9
10
11
12
A
Rep 1
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
1000
B
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
2000
C
Rep 3
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
4000
D
Rep 4
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
8000
E
Rep 5
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
16000
F
Rep 6
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
32000
G
Rep 7
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
64000
H
Rep 8
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
128000
NC
PC
sample1
sample2
sample3
sample4
• Cutpoint = Mean(NC) * Overall CPF (from Step
1)
• Use the cutpoint for endpoint titer calculation
Comparing Cutpoint Factors
• Are CPFs the same at different setups?
– Reagent lot, serum type, etc
– Important for process improvement
– Decision making
• How to compare CPF with repeated
measures?
– A subject may contribute multiple samples
Statistical Treatment of CPF
• Note for a certain plate,
CPF = (Mean+ cα*SD)/Mean = 1+ cα*CV
• CV has a noncentral t-distribution (Johnson and
Welch, 1967)
– Computationally difficult (though tools do exist)
– Hard to extend to repeated measure scenarios
• Alternative: Log-transform
– In many cases, the signals (relative light units) are
approximately log-normal
Example: 25 Samples
130 140 150 160 170 180 190 200 210
Normal(158.68,17.8202)
LogNormal(5.06118,0.10533)
• Goodness of fit
– Normal: p = 0.02 (S-W test)
– LogNormal: p = 0.10 (Kolmogorov’s D)
Log-transform Approach
2
log
normal
(

,

)
• It is well known that if X ~
then CV(X) = exp( 2 )  1
• When σ is small, exp( 2 ) 1  
• So statistical inference can be based upon
variability of the logged data
Example: 25 Samples
130 140 150 160 170 180 190 200 210
Normal(158.68,17.8202)
LogNormal(5.06118,0.10533)
• Noncentral t-distribution
– CV = (0.088, 0.157)
– CPF= (1.145, 1.258)
• Log-transform
– CV = (0.084, 0.150)
– CPF = (1.138, 1.247)
Homogeneity of Variability
• Levene’s test
– Fit 1st ANOVA to get residual variability estimate
– Fit 2nd ANOVA on abs(residual) to test equal variance
– Readily extends to repeated-measure cases
• Models:
– i: Lot; j: replicate; k: subject
– 1st ANOVA: RLUijk = μ + replicatekj(i) + subjectk + εijk
=> Get residuals rijk
– 2nd ANOVA
• Within-lot:
• Between-lot:
rijk = μ + replicatej(i) + εijk
rijk = μ + loti + εijk
Example
Variability Chart for Log(RLU)
10.0
Log(RLU)
• Two different reagent lots
• Three plates at each lot
• Samples from 30 subjects
10.5
9.5
9.0
8.5
• Results:
a2
a3
b1
1
b2
b3
2
Rep w ithin Lot
0.20
0.15
Std Dev
– In Lot 1, Plate a2 has
higher variability than other
plates
– No significant difference in
variability between Lots 1
and 2
a1
0.10
0.05
0.00
a1
a2
1
Rep w ithin Lot
a3
b1
b2
2
b3
Discussions
• Cutpoint analysis is crucial in various
applications of the endpoint titer method
• Cutpoint in most cases depends on the
plate, experimental parameters, etc. So
using a fixed cutpoint is not recommended
• Uncertainty in CPF will translate to error in
the endpoint titer
Acknowledgements
• Daniel Baltrukonis – Immunotox CoE
• Jessica Duffy – Immunotox CoE
• David Potter – PharmaTx Statistics